Afuresertib vs Capivasertib

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

HR+/HER2- Metastatic Breast Cancer

Shared mechanism: AKT (inhibitor) · full HR+/HER2- Metastatic Breast Cancer pipeline

Afuresertib

Developed by Laekna Limited under a licence from Novartis

Phase 3 in HR+/HER2- Metastatic Breast Cancersmall molecule (AKT inhibitor)
Partial signal

NCT04851613 · Phase 3 · active, not recruiting

This was a randomized, quadruple-masked Phase 3 trial with 256 participants. Its primary endpoint was met according to the sponsor's announcement of 2026-04-15. The result comes from the sponsor's announcement and the sources read give no power calculation, so the grade is moderate.

Reported efficacy

Phase I: Overall Response Rate (ORR) based on RECIST 1.1 (Phase I: Change from Baseline beginning at Cycle 3 Day 1 and then every 8 weeks × 40 weeks then every 3 months through study completion, an average of 1 year (each cycle is 28 days)); Phase III: Progression Free Survival (PFS) based on RECIST 1.1, as assessed by investigators (Phase III:Change from Baseline beginning at Cycle 3 Day 1 and then every 8 weeks for the first 12 months, then every 3 months through study completion): Primary endpoint, progression-free survival: median 7.6 months with afuresertib plus fulvestrant vs 2.0 months with placebo plus fulvestrant (sponsor topline, 2026-04-15). (met)

Result source: NCT04851613

Capivasertib

Marketed by AstraZeneca and partners

Approved in HR+/HER2- Metastatic Breast Cancersmall molecule
Reliable signal

NCT04305496 · Phase 3 · active, not recruiting

Patients were randomized to capivasertib or matching placebo, both added to fulvestrant, with participants, care providers, investigators and outcomes assessors all masked. With 355 vs 353 patients in the global cohort, the primary endpoint of progression-free survival was significantly longer with capivasertib (hazard ratio 0.60, 95% CI 0.51 to 0.71, p<0.001).

Next expected readout: December 2026 · NCT05563220 (registry estimate)

Reported efficacy

Progression Free Survival: Overall Population (Months) in the Global Cohort (Assessed every 8 weeks for the first 18 months and every 12 weeks thereafter, from randomization to radiological progression.); Progression Free Survival: Overall Population (Percentage) in the Global Cohort (Assessed every 8 weeks for the first 18 months and every 12 weeks thereafter, from randomization to radiological progression.); Progression Free Survival: Altered Population (Months) in the Global Cohort (Assessed every 8 weeks for the first 2 years following objective disease progression or treatment discontinuation and then every 12 weeks.); Progression Free Survival: Altered Population (Percentage) in the Global Cohort (Assessed every 8 weeks for the first 2 years following objective disease progression or treatment discontinuation and then every 12 weeks.); Progression Free Survival: Overall Population (Months) in the China Cohort (Assessed every 8 weeks for the first 18 months and every 12 weeks thereafter, from randomization to radiological progression.); Progression Free Survival: Overall Population (Percentage) in the China Cohort (Assessed every 8 weeks for the first 18 months and every 12 weeks thereafter, from randomization to radiological progression.); Progression Free Survival: Altered Population (Months) in the China Cohort (Assessed every 8 weeks for the first 2 years following objective disease progression or treatment discontinuation and then every 12 weeks.); Progression Free Survival: Altered Population (Percentage) in the China Cohort (Assessed every 8 weeks for the first 2 years following objective disease progression or treatment discontinuation and then every 12 weeks.): Progression Free Survival: Overall Population (Months) in the Global Cohort (Assessed every 8 weeks for the first 18 months and every 12 weeks thereafter, from randomization to radiological progression.): Capivasertib + Fulvestrant (Global + China Cohort) 7.2 Months (95% CI 5.5 to 7.4) vs Placebo + Fulvestrant (Global + China Cohort) 3.6 Months (95% CI 2.8 to 3.7) (met)

Result source: NCT04305496

Results for HR+/HER2- Metastatic Breast Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAfuresertibCapivasertib
PFS, median—Trial running · NCT048516137.2 vs 3.6+3.6 vs placebon 355NCT04305496
4 other results
OS, median—Trial running · NCT0485161332.8n 54NCT01625286
ORR—Trial running · NCT04851613—Trial running · NCT04305496
Clinical benefit rate—Trial running · NCT04851613—Trial running · NCT04305496

PFS, median

Afuresertib
—Trial running · NCT04851613
Capivasertib
7.2 vs 3.6+3.6 vs placebon 355NCT04305496
4 other results

OS, median

Afuresertib
—Trial running · NCT04851613
Capivasertib
32.8n 54NCT01625286

ORR

Afuresertib
—Trial running · NCT04851613
Capivasertib
—Trial running · NCT04305496

Clinical benefit rate

Afuresertib
—Trial running · NCT04851613
Capivasertib
—Trial running · NCT04305496
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Afuresertib
Primary endpoint, progression-free survival: median 7.6 months with afuresertib plus fulvestrant vs 2.0 months with placebo plus fulvestrant (sponsor topline, 2026-04-15). NCT04851613 · Phase 3 · design grade: moderate · reviewed ClinicalTrials.gov result

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Afuresertib: 0 of 4 rows · Capivasertib: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricCapivasertib
Dropout rate
—Capi (China Cohort)a
NCT04305496 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 10 more results
—Capi (Global Cohort)
NCT04305496 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
50%640 mg bd
NCT01625286 · Phase 1/2 · combination
—640 mg bd
NCT01625286 · Phase 1/2 · combination
50%560 mg bd
NCT01625286 · Phase 1/2 · combination
100%480 mg bd
NCT01625286 · Phase 1/2 · combination
100%400 mg bd
NCT01625286 · Phase 1/2 · combination
—400 mg bd
NCT01625286 · Phase 1/2 · combination
100%360 mg bd
NCT01625286 · Phase 1/2 · combination
—360 mg bd
NCT01625286 · Phase 1/2 · combination
25.9%Part B AZD5363
NCT01625286 · Phase 1/2 · combination
Discontinued due to AEs
—Capi (China Cohort)a
NCT04305496 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 10 more results
—Capi (Global Cohort)
NCT04305496 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
0%640 mg bd
NCT01625286 · Phase 1/2 · combination
—640 mg bd
NCT01625286 · Phase 1/2 · combination
0%560 mg bd
NCT01625286 · Phase 1/2 · combination
16.7%480 mg bd
NCT01625286 · Phase 1/2 · combination
0%400 mg bd
NCT01625286 · Phase 1/2 · combination
—400 mg bd
NCT01625286 · Phase 1/2 · combination
0%360 mg bd
NCT01625286 · Phase 1/2 · combination
—360 mg bd
NCT01625286 · Phase 1/2 · combination
3.7%Part B AZD5363
NCT01625286 · Phase 1/2 · combination
Serious AEs
28.2%Capi (China Cohort)a
NCT04305496 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 10 more results
16.1%Capi (Global Cohort)
NCT04305496 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
—640 mg bd
NCT01625286 · Phase 1/2 · combination
37.5%640 mg bd
NCT01625286 · Phase 1/2 · combination
25%560 mg bd
NCT01625286 · Phase 1/2 · combination
66.7%480 mg bd
NCT01625286 · Phase 1/2 · combination
—400 mg bd
NCT01625286 · Phase 1/2 · combination
14.3%400 mg bd
NCT01625286 · Phase 1/2 · combination
—360 mg bd
NCT01625286 · Phase 1/2 · combination
0%360 mg bd
NCT01625286 · Phase 1/2 · combination
24.1%Part B AZD5363
NCT01625286 · Phase 1/2 · combination
Most frequent reported AEs
a
diarrhoea 60.6% (placebo 11.3%)
hyperglycaemia 57.7% (placebo 17.7%)
anaemia 31% (placebo 17.7%)
NCT04305496 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 7 more results
diarrhoea 71.8% (placebo 11.3%)
nausea 34.4% (placebo 3.2%)
rash 21.7% (placebo 6.5%)
NCT04305496 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
640 mg bd
diarrhoea 87.5% (placebo 27.3%)
asthenia 62.5% (placebo 12.7%)
dizziness 62.5% (placebo 7.3%)
NCT01625286 · Phase 1/2 · combination
560 mg bd
diarrhoea 91.7% (placebo 27.3%)
nausea 66.7% (placebo 23.6%)
anaemia 50% (placebo 27.3%)
NCT01625286 · Phase 1/2 · combination
480 mg bd
diarrhoea 100% (placebo 27.3%)
nausea 83.3% (placebo 23.6%)
vomiting 66.7% (placebo 14.5%)
NCT01625286 · Phase 1/2 · combination
400 mg bd
asthenia 85.7% (placebo 12.7%)
diarrhoea 85.7% (placebo 27.3%)
myalgia 42.9% (placebo 21.8%)
NCT01625286 · Phase 1/2 · combination
360 mg bd
diarrhoea 100% (placebo 27.3%)
alopecia 60% (placebo 49.1%)
nausea 60% (placebo 23.6%)
NCT01625286 · Phase 1/2 · combination
diarrhoea 75.9% (placebo 27.3%)
alopecia 51.9% (placebo 49.1%)
nausea 38.9% (placebo 23.6%)
NCT01625286 · Phase 1/2 · combination

Notes

  1. aPopulation comparability has not been reviewed for 9 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Capivasertib

PFS 7.2 vs 3.6 placebo months
time to event · months
NCT04305496 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 4 more results
7.3 vs 3.1 placebo months
NCT04305496 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
6.9 vs 2.8 placebo months
NCT04305496 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
5.7 vs 1.9 placebo months
NCT04305496 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
10.9 vs 8.4 placebo months
NCT01625286 · Phase 1/2 · combination
PFS 51.8% (n=355) vs 32% (n=353) placebo @ 26wk
responder rate · % of participants
NCT04305496 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 11 more results
40.9% (n=355) vs 24.4% (n=353) placebo @ 39wk
NCT04305496 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
28.5% (n=355) vs 18.4% (n=353) placebo @ 52wk
NCT04305496 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
53.4% (n=155) vs 29.6% (n=134) placebo @ 26wk
NCT04305496 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
42% (n=155) vs 21.6% (n=134) placebo @ 39wk
NCT04305496 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
28.2% (n=155) vs 15.8% (n=134) placebo @ 52wk
NCT04305496 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
53.9% (n=71) vs 24.5% (n=63) placebo @ 26wk
NCT04305496 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
40.9% (n=71) vs 24.5% (n=63) placebo @ 39wk
NCT04305496 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
29.6% (n=71) vs 19.1% (n=63) placebo @ 52wk
NCT04305496 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
46.3% (n=71) vs 14.3% (n=63) placebo @ 26wk
NCT04305496 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
23.1% (n=71) vs 14.3% (n=63) placebo @ 39wk
NCT04305496 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
6.9% (n=71) vs 14.3% (n=63) placebo @ 52wk
NCT04305496 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Tumor Size -15.7% (n=7) vs -25.4% (n=55) placebo @ 12wk640 mg bd
percent change · % of baseline
NCT01625286 · Phase 1/2 · combination
show 5 more results
-11% (n=10) vs -25.4% (n=55) placebo @ 12wk560 mg bd
NCT01625286 · Phase 1/2 · combination
-10.2% (n=4) vs -25.4% (n=55) placebo @ 12wk480 mg bd
NCT01625286 · Phase 1/2 · combination
-18.3% (n=5) vs -25.4% (n=55) placebo @ 12wk400 mg bd
NCT01625286 · Phase 1/2 · combination
-19.1% (n=5) vs -25.4% (n=55) placebo @ 12wk360 mg bd
NCT01625286 · Phase 1/2 · combination
-34.2% (n=53) vs -25.4% (n=55) placebo @ 12wk
NCT01625286 · Phase 1/2 · combination
ORR 12.5% (n=8) vs 42.9% (n=56) placebo @ 12wk640 mg bd
absolute value · percentage points
NCT01625286 · Phase 1/2 · combination
show 11 more results
25% (n=8) vs 57.1% (n=56) placebo640 mg bd
NCT01625286 · Phase 1/2 · combination
41.7% (n=12) vs 42.9% (n=56) placebo @ 12wk560 mg bd
NCT01625286 · Phase 1/2 · combination
0% (n=12) vs 57.1% (n=56) placebo560 mg bd
NCT01625286 · Phase 1/2 · combination
0% (n=6) vs 42.9% (n=56) placebo @ 12wk480 mg bd
NCT01625286 · Phase 1/2 · combination
0% (n=6) vs 57.1% (n=56) placebo480 mg bd
NCT01625286 · Phase 1/2 · combination
0% (n=7) vs 42.9% (n=56) placebo @ 12wk400 mg bd
NCT01625286 · Phase 1/2 · combination
14.3% (n=7) vs 57.1% (n=56) placebo400 mg bd
NCT01625286 · Phase 1/2 · combination
0% (n=5) vs 42.9% (n=56) placebo @ 12wk360 mg bd
NCT01625286 · Phase 1/2 · combination
20% (n=5) vs 57.1% (n=56) placebo360 mg bd
NCT01625286 · Phase 1/2 · combination
50% (n=54) vs 42.9% (n=56) placebo @ 12wk
NCT01625286 · Phase 1/2 · combination
59.3% (n=54) vs 57.1% (n=56) placebo
NCT01625286 · Phase 1/2 · combination
Duration of Response 8.3 vs 8.2 placebo months
time to event · months
NCT01625286 · Phase 1/2 · combination
Duration of Response Rate at 6 48.1% (n=54) vs 37.5% (n=56) placebo
ratio to baseline · % of baseline
NCT01625286 · Phase 1/2 · combination
Overall Survival 32.8 vs NA placebo months
time to event · months
NCT01625286 · Phase 1/2 · combination

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Afuresertib's landscape · Capivasertib's landscape